Ligand Pharmaceuticals (LGND) EBT (2010 - 2026)

Ligand Pharmaceuticals has reported EBT for 17 years, with the latest figure at -$24.3 million in Q1 2026.

• Quarterly EBT rose 51.66% year-over-year to -$24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 214.76% YoY) and the FY2025 annual result came in at $159.0 million, up 6212.95% from the prior year.
• EBT eased to -$24.3 million in Q1 2026 per LGND's latest filing, from $56.8 million in the prior quarter.
• Over five years, EBT peaked at $141.1 million in Q3 2025 and troughed at -$65.4 million in Q2 2024.
• A 5-year average of $13.9 million and a median of $8.7 million in 2022 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2025: EBT slumped 2162.13% in 2024, then jumped 2326.49% in 2025.
• Over 5 years, EBT stood at $24.1 million in 2022, then dropped by 29.18% to $17.1 million in 2023, then slumped by 329.28% to -$39.2 million in 2024, then surged by 244.85% to $56.8 million in 2025, then slumped by 142.72% to -$24.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$24.3 million, $56.8 million, and $141.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.